New Alliance Targets Brain in Rare Disease Gene Therapy Battle

NEW YORK, NY – May 05, 2026 – A landmark collaboration announced today aims to strike at the neurological heart of Tuberous Sclerosis Complex (TSC), a rare genetic disease, by deploying a novel gene therapy designed to breach the brain's formidable defenses. Biotechnology firm Apertura Gene Therapy and the influential patient advocacy group TSC Alliance are joining forces to advance treatments that could fundamentally alter the course of the debilitating disorder.

The partnership will leverage Apertura's proprietary TfR1 CapX™, a highly engineered delivery vehicle designed to carry a functional copy of the TSC1 or TSC2 gene directly into the central nervous system after a simple intravenous injection. This approach holds the potential to address the most severe symptoms of the disease, which current therapies can only manage.

The Neurological Burden of TSC

Tuberous Sclerosis Complex is a rare genetic condition that causes non-cancerous tumors to grow in vital organs, including the brain, heart, kidneys, and lungs. While the disease can manifest throughout the body, its neurological consequences represent the greatest burden for the roughly 50,000 people affected in the United States and nearly one million worldwide.

Approximately 85% of individuals with TSC suffer from seizures, and for two-thirds of them, the epilepsy is refractory, meaning it does not respond to standard medications. Beyond seizures, the majority of patients also face a spectrum of TSC-Associated Neuropsychiatric Disorders (TAND), which can include cognitive impairment, autism spectrum disorder, and severe behavioral challenges. While treatments like mTOR inhibitors have marked a significant advance in managing tumor growth and some symptoms, they require lifelong administration and do not correct the underlying genetic defect.

"Gene therapy offers the clearest path to the treatment of TSC by providing a functional copy of either TSC1 or TSC2," said Dean Aguiar, Ph.D., TSC Alliance Executive Vice President of Translational Research. The challenge, however, has always been delivery.

A 'Molecular Key' to Unlock the Brain

Treating neurological disorders is notoriously difficult due to the blood-brain barrier (BBB), a highly selective membrane that protects the brain from toxins and pathogens but also blocks most medicines. Apertura's technology is designed to circumvent this obstacle.

The company's TfR1 CapX™ is an adeno-associated virus (AAV) capsid—the protein shell of a harmless virus used to deliver genetic material—that has been specifically engineered to act as a molecular key. It targets the human transferrin receptor 1 (hTfR1), a protein abundant on the surface of the BBB's cells. By binding to this receptor, the capsid effectively hijacks a natural transport system the body uses to shuttle iron into the brain, allowing it to be ferried across the barrier.

Preclinical research on a predecessor capsid, published in the journal Science, showed this method could boost gene expression in the central nervous system of specialized mice by 40 to 50 times compared to AAV9, a commonly used vector. Apertura states its second-generation TfR1 CapX™ demonstrates even greater efficiency at lower doses, which could significantly reduce potential side effects like liver toxicity.

"Apertura's TfR1 CapX delivery vehicle offers hope that we can deliver TSC1 or TSC2 to diverse cell types," Aguiar noted. "Broad distribution, particularly in the brain, will be critical to the effectiveness of the treatment."

Patient Power Forging a New Research Model

This collaboration is more than a scientific endeavor; it represents a powerful shift in how therapies for rare diseases are developed. With traditional funding for rare disease research often limited, patient advocacy organizations like the TSC Alliance have evolved from support networks into crucial drivers of innovation.

The partnership aligns with the mission of the TSC Alliance's Preclinical Consortium, an initiative that provides researchers with standardized, reproducible preclinical models and outcome measures. This platform de-risks the early, critical stages of drug development for industry and academic partners, making rare disease research a more viable proposition. This model of "venture philanthropy" allows patient groups to directly invest in and guide the development of the most promising therapies for their communities.

"Over the last two decades the TSC Alliance has invested in and built research resources to accelerate drug development in TSC," said Kari Luther Rosbeck, TSC Alliance President & CEO. "These resources, like our Preclinical Consortium, combined with our partnership with Apertura, allow us to meaningfully explore gene replacement therapy as a novel treatment avenue, fulfilling one of the desired outcomes of the TSC community."

This sentiment was echoed by Apertura. "At a time when traditional sources of funding for rare disease research are limited, collaborations between patient advocacy groups and industry are extremely important to help advance important preclinical research," said Christopher Davis, Ph.D., Director of Nonclinical and Translational Research at Apertura Gene Therapy.

Navigating the Path to Clinical Reality

The collaboration enters a gene therapy market that is rapidly maturing. The U.S. Food and Drug Administration (FDA) has already approved several gene therapies for rare neurological disorders, including Zolgensma for spinal muscular atrophy and Skysona for cerebral adrenoleukodystrophy, demonstrating a clear regulatory path for such innovative treatments.

Furthermore, the FDA has created pathways like Accelerated Approval to speed the availability of drugs for serious conditions with high unmet needs. Apertura has already engaged with the agency through an INTERACT meeting for its TSC1 program, receiving feedback that supports a streamlined preclinical strategy. IND-enabling studies—the final preclinical step before seeking permission for human trials—are now underway.

While the program targeting the TSC2 gene is at an earlier stage, the progress on the TSC1 front is a promising sign. Apertura has also indicated that it expects partner programs utilizing its TfR1 CapX™ technology to enter clinical trials within the next 12 months, signaling growing confidence in the delivery platform's potential across multiple diseases. This strategic alliance, announced during TSC Awareness Month, marries cutting-edge science with dedicated patient advocacy, forging a promising new path toward a potential cure for a community long in need of a breakthrough.